aibio
Financings ·
Rezolute sells 1,295,383 shares in private placement for $4,209,994.75
An 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement.
RZLT Rezolute, Inc.
Rezolute (RZLT) news RZLT offering news
Latest Rezolute news
- Financings
Rezolute prices registered direct offering of about $90 million at $3.25 per share
Rezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price.
What Rezolute does
Rezolute, Inc. is a late-stage rare disease company developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds an allosteric site on the insulin receptor. The company says it is being developed to treat any form of HI, and that its dose dependent pharmacokinetics have a half-life greater than 2 weeks. The Phase 3 sunRIZE study in congenital HI did not meet its primary endpoint or its key secondary endpoint at the defined Week 24 window, as announced on December 11, 2025. The company reports that continuous glucose monitoring endpoints showed consistent reductions in hypoglycemia compared to placebo, and it shared these data at the Pediatric Endocrine Society Annual Meeting on May 1, 2026. The company met with the FDA on March 17, 2026, under its Breakthrough Therapy Designation. In September 2026 the agency said it was still reviewing the submission, and the text states that there is no specific timeline for feedback. An open-label extension is ongoing, with 56 participants remaining in it.
| Product or program | What it is | Stage |
|---|---|---|
| ersodetug | Allosteric insulin receptor antibody for refractory hypoglycemia caused by hyperinsulinism | Phase 3 sunRIZE did not meet primary endpoint; FDA reviewing submission |
Rezolute annual financials
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $53.8 million | $61.5 million |
| Net income (loss) | -$77.6 million | -$74.4 million |
| Cash from operations | -$64.6 million | -$69.1 million |
| Cash and equivalents | $10.6 million | $94.1 million |
| Short-term investments | $97.2 million | $73.8 million |
Questions about Rezolute
Has Rezolute raised money recently?
Our latest story on this, dated Jun 13, 2025: "Rezolute sells 1,295,383 shares in private placement for $4,209,994.75". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Rezolute?
Rezolute, Inc. trades under the ticker RZLT on NASDAQ.
Where is Rezolute listed?
Rezolute, Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A2QEWP; LSX:A2QEWP.
What is the SEC CIK of Rezolute?
The SEC Central Index Key (CIK) for Rezolute, Inc. is 1509261. Its filings are on SEC EDGAR.
How many shares does Rezolute have outstanding?
96,722,333 shares as of 2026-09-21, per the cover page of its 10-K filed 2026-09-24.
Which country or territory is Rezolute listed under?
Our directory records Rezolute, Inc. under United States.
What does Rezolute do?
Our directory classifies Rezolute, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Rezolute?
The ISIN recorded for Rezolute, Inc. is US76200L3096.
Does aibio.space cover Rezolute?
aibio.space lists Rezolute, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Rezolute incorporated?
SEC records list its state or country of incorporation as NV.
What does Rezolute develop?
Rezolute, Inc. is a late-stage rare disease company developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds an allosteric site on the insulin receptor.
What is ersodetug from Rezolute?
ersodetug: Allosteric insulin receptor antibody for refractory hypoglycemia caused by hyperinsulinism Stage: Phase 3 sunRIZE did not meet primary endpoint; FDA reviewing submission.
Is Rezolute profitable?
Rezolute, Inc. reported a net loss of $77.6 million for the fiscal year ended Jun 30, 2026, and used $64.6 million of cash in operations, per its annual report to the SEC.
How much does Rezolute spend on research and development?
$53.8 million in the fiscal year ended Jun 30, 2026, per its annual report.
How much cash does Rezolute have?
$107.8 million in cash and short-term investments at Jun 30, 2026, per its 10-K.
Investor discussion: Rezolute
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,1.02,5.02). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Rezolute, Inc.
- CIK
- 1509261
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- RZLT (Nasdaq)
- State or country of incorporation
- NV
- Fiscal year ends
- June 30
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065
- Phone
- 650-206-4507
- Shares outstanding
- 96,722,333 as of 2026-09-21 (10-K filed 2026-09-24)
- Former names
- AntriaBio, Inc.; FITS MY STYLE INC
Recent filings
Listing details
- Company
- Rezolute, Inc.
- Ticker
- RZLT
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US76200L3096
- Other listed symbols
- LS:A2QEWP; LSX:A2QEWP
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction